RPL24B Antibody

What are the recommended applications and dilutions for RPL24 antibody in different experimental techniques?

RPL24 antibody (17082-1-AP) has been validated for multiple research applications with specific dilution recommendations for optimal results. The antibody can be effectively used in Western blot (WB), immunoprecipitation (IP), immunohistochemistry (IHC), and immunofluorescence (IF)/immunocytochemistry (ICC) .

For optimal results, researchers should titrate the antibody in their specific testing systems as results may be sample-dependent . The antibody has been positively tested in WB applications with A549, HEK-293, and Jurkat cells, while IP applications have been validated in HEK-293 cells .

What tissue samples have been validated for RPL24 antibody detection using immunohistochemistry?

RPL24 antibody (17082-1-AP) has been validated for IHC detection in multiple human tissues, providing researchers with reliable options for translational studies. Positive IHC signals have been detected in:

• Human placenta tissue

• Human kidney tissue

• Human liver tissue

• Human spleen tissue

• Human ovary tissue

For optimal antigen retrieval, it is recommended to use TE buffer at pH 9.0, though citrate buffer at pH 6.0 can serve as an alternative . When performing IHC staining, researchers typically incubate the antibody at room temperature for approximately 2 hours at a dilution of 1:50 in PBS buffer, followed by staining with an appropriate immunohistochemistry kit .

What are the proper storage conditions for maintaining RPL24 antibody activity?

Proper storage is critical for maintaining antibody functionality and ensuring experimental reproducibility. The RPL24 antibody (17082-1-AP) should be stored at -20°C where it remains stable for one year after shipment . The antibody is supplied in a storage buffer consisting of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

For long-term storage, aliquoting is unnecessary for -20°C storage, which simplifies laboratory management. It's important to note that 20μl size preparations contain 0.1% BSA . These storage conditions help maintain antibody integrity and performance across multiple experimental applications.

How can RPL24 antibody be used to study its role as a prognostic biomarker in cancer research?

RPL24 has emerged as a potential prognostic biomarker in cervical cancer (CC), with significant implications for treatment efficacy assessment. Research has demonstrated that RPL24 expression increases after concurrent chemoradiotherapy (CCRT) in most CC patients, and higher expression levels correlate with better prognosis .

To study RPL24 as a prognostic marker, researchers should:

• Collect patient tissue samples before and after treatment (e.g., CCRT)

• Perform immunohistochemical staining using RPL24 antibody at a 1:50 dilution

• Evaluate staining results using a standardized scoring system (negative -, weak positive +, positive ++, strongly positive +++)

• Correlate RPL24 expression with clinical outcomes using Kaplan-Meier survival analysis

What methods should be used to overexpress RPL24 in experimental models?

For researchers investigating the functional role of RPL24, establishing overexpression models is essential. Based on published protocols, RPL24 overexpression can be achieved through both transient and stable transfection methods:

For transient overexpression:

• Clone full-length homo sapiens RPL24 sequences (NM_000986.4) into an expression vector such as pcDNA3.0

• Transfect target cells (e.g., SiHa cells) using Lipofectamine 2000 reagent following the manufacturer's protocol

• Screen positive clones using media containing G418

• Confirm transfection efficiency via Western blot analysis

For stable overexpression:

• Clone RPL24 into a lentiviral vector (e.g., Pez-Lv105)

• Produce recombinant lentivirus according to manufacturer's protocol

• Infect target cells and select stable integrants using appropriate antibiotics

• Confirm stable expression through Western blot analysis

These approaches have been successfully used to demonstrate that RPL24 overexpression suppresses tumor growth both in vitro and in vivo .

How should researchers design in vivo experiments to study RPL24 function in tumor development?

In vivo studies are critical for validating the tumor-suppressive role of RPL24. A validated methodology for studying RPL24 in tumor development involves:

• Animal model selection: 6-week-old female NOD/SCID mice housed under standard conditions (12-hour light/dark cycle, 22±0.5°C, 40-70% relative humidity)

• Cell line preparation: Establish stable cell lines overexpressing RPL24 and appropriate control cell lines

• Tumor induction: Inject 0.2 ml of single-cell suspension (approximately 3×10^6 cells) subcutaneously

• Monitoring: Track tumor formation rate, volume, and weight over time

• Analysis: Sacrifice mice at predetermined endpoints, collect tumors, and perform immunohistochemical and molecular analyses

Using this approach, researchers have demonstrated that mice injected with RPL24-transfected SiHa cells showed markedly better general health status with reduced tumor formation rates compared to control groups . Tumors from the RPL24 overexpression group grew more slowly and were smaller in both volume and weight compared to controls, supporting RPL24's tumor-suppressive role .

What explains the discrepancy between calculated and observed molecular weights for RPL24?

Researchers often encounter a discrepancy between theoretical and observed molecular weights when detecting RPL24 by Western blot. The calculated molecular weight of RPL24 is 18 kDa, while the observed molecular weight typically falls between 21-23 kDa . This difference can be attributed to:

• Post-translational modifications (phosphorylation, ubiquitination, etc.)

• Protein-protein interactions that alter migration patterns

• Structural conformations affecting detergent binding during SDS-PAGE

When validating RPL24 antibody specificity, researchers should be aware of this discrepancy and look for bands in the 21-23 kDa range rather than at the calculated 18 kDa . This variance between theoretical and observed molecular weights is common for many proteins and does not indicate antibody non-specificity.

How can researchers validate RPL24 antibody specificity in their experimental systems?

Ensuring antibody specificity is crucial for obtaining reliable research results. To validate RPL24 antibody specificity:

• Include appropriate positive controls: Use cell lines with confirmed RPL24 expression (A549, HEK-293, or Jurkat cells for WB; HEK-293 cells for IP; HeLa cells for IF/ICC)

• Perform knockdown/knockout validation: Compare antibody signal between wild-type and RPL24 knockdown/knockout samples

• Use multiple detection methods: Confirm results across different techniques (WB, IP, IHC)

• Include negative controls: Evaluate non-specific binding using isotype control antibodies or secondary antibody-only controls

When conducting immunohistochemical analyses, researchers should have two independent reviewers evaluate staining results to minimize scoring errors and ensure reproducibility . This approach helps maintain objectivity when assessing staining intensity and the percentage of positively stained cells.

What factors should be considered when interpreting RPL24 expression data in clinical samples?

When analyzing RPL24 expression in clinical samples for prognostic studies, researchers should consider several factors to ensure accurate interpretation:

• Patient characteristics: Age, clinical stage, treatment history

• Treatment response: Complete response (CR), partial response (PR), or stable disease (SD)

• Imaging correlates: Apparent diffusion coefficient (ADC) values from imaging studies

• Statistical approaches: Use appropriate statistical methods (Kaplan-Meier, Spearman correlation, unpaired t-tests)

For clinical correlations, it's recommended to perform at least three independent experiments and present data as mean ± standard deviation (SD) . Fisher's exact probability test should be used for count data, while the Spearman test is appropriate for analyzing correlations between RPL24 expression before and after treatment .

The following table illustrates how clinical data can be organized when studying RPL24 expression in relation to treatment response:

How does RPL24 expression correlate with cell cycle progression in cancer cells?

RPL24 expression has been linked to cell cycle regulation in cancer cells, particularly affecting the G2/M phase. In vitro studies with cervical cancer cell lines have demonstrated that after cisplatin (CDDP) treatment, the proportion of cells in G2/M phase increases, accompanied by elevated expression of RPL24 .

To study this correlation:

• Treat cancer cell lines (e.g., HeLa and SiHa) with CDDP or control treatments

• Perform cell cycle analysis using flow cytometry

• Extract proteins and conduct Western blotting to detect RPL24, CCNB1 (a mitotic marker), and p53

• Use β-actin as an internal control for protein expression normalization

Research has shown that RPL24, CCNB1, and p53 proteins are overexpressed in SiHa and HeLa cells after CDDP treatment compared to control treatments . This suggests that RPL24 may play a role in the G2/M phase arrest observed in response to chemotherapy, potentially contributing to its tumor-suppressive effects.

What is the subcellular localization of RPL24 and how might this inform its non-canonical functions?

While RPL24 is primarily known as a component of the ribosome involved in protein synthesis, its subcellular localization pattern suggests additional functions. Fractionation studies in HEK293T cells have demonstrated that RPL24 is found in both nuclear and cytoplasmic fractions .

This dual localization suggests RPL24 may have extraribosomal functions beyond its canonical role in translation. Recent research indicates that RPL24 may be involved in microRNA (miRNA) processing and transfer RNA fragment (tRF) production, similar to its role in Arabidopsis thaliana . This suggests an evolutionarily conserved function in RNA metabolism that extends beyond ribosome biogenesis.

To study RPL24 subcellular localization:

• Perform cell fractionation to separate nuclear and cytoplasmic components

• Analyze fraction purity using markers for nuclear and cytoplasmic compartments

• Detect RPL24 distribution using Western blot or immunofluorescence

• Correlate localization with potential extraribosomal functions

Understanding RPL24's subcellular distribution can provide insights into its potential roles in RNA metabolism, gene expression regulation, and other cellular processes beyond protein synthesis.

How might RPL24's role in miRNA processing inform new research avenues?

The discovery that RPL24 regulates miRNA processing in Arabidopsis thaliana and potentially in mammalian systems opens exciting new research directions . This evolutionarily conserved function suggests RPL24 may have broader regulatory roles in gene expression than previously recognized.

For researchers interested in exploring this emerging area:

• Design experiments to identify miRNAs affected by RPL24 manipulation (overexpression/knockdown)

• Perform RNA immunoprecipitation (RIP) assays to identify direct interactions between RPL24 and miRNA precursors

• Use high-throughput sequencing to profile miRNA changes upon RPL24 modulation

• Investigate the functional consequences of RPL24-mediated miRNA regulation on target genes

These approaches could reveal new mechanisms by which RPL24 influences cellular processes and potentially identify novel therapeutic targets in diseases where miRNA dysregulation plays a role.

What are the implications of RPL24's dual role in cancer progression?

The literature reveals apparently contradictory roles for RPL24 in cancer, suggesting context-dependent functions. While elevated RPL24 expression predicts better prognosis in cervical cancer patients after CCRT , other studies indicate that RPL24 may confer resistance to certain therapies in hepatocellular carcinoma .

These contradictions highlight important research questions:

• How does tissue context influence RPL24's role in cancer biology?

• What molecular partners interact with RPL24 to determine its pro- or anti-tumor effects?

• How do different therapeutic interventions modulate RPL24 expression and function?